Purecell Group

Advancing innovation from discovery to application.

Medicine for the Future Today

We have assisted clients in Australia and internationally to translate their discoveries into commercial entities utilizing experienced scientists as well as regulatory personnel, IP specialists and Australian Government Research Grant advisors.

The Purecell Group based in Sydney and Melbourne, Australia is a Translational Research Centre.

TWO SCIENTISTS WITH OVER 30 YEARS EXPERIENCE

Andrew French

Chief Scientific Officer

Prof. Andrew French is a translational scientist with over 20 years’ experience in lead scientific roles for companies within the Australian and International Biotechnology and Medical sectors. He received his PhD in the field of Reproductive Technologies from the Departments of Obstetrics and Gynaecology and Animal Sciences, The University of Adelaide.

Training in Reproductive and Stem cell biology, he has held senior academic positions at leading Australian Universities. His focus and major interests are the successful transfer of technologiesto different research and commercial platforms. Notably his application of nuclear transfer and stem cell biology to numerous species is internationally recognised. Moving to industry, he has developed a reputation for delivering value to translating innovationsto preclinical studies including animal reproduction, breast regeneration, vaccine development, surgical trauma care, nerve and cardiovascular repair and percutaneous coronary intervention. Further clinical translational services, comprising regenerative medicine strategies have involved stem cells, cytokines, exosomes and blood biologics for osteoarthritis, cerebrovascular disease, and cosmetic application. Working in Australia, New Zealand, USA, Uruguay, and Singapore, he has considerable experience in managing cross-discipline teams and investments. Andrew currently holds an Honorary appointment at the Faculty of Veterinary and Agricultural Science, The University of Melbourne and Adjunct appointment at the Australian Regenerative Medicine Institute, Monash University.

Gilles Guillemin

Senior Scientific Advisor

Prof Guillemin has been working in the field of Neuroimmunology and inflammation for approximately 30 years. He is an experienced researcher who moved to Australia in 1997. He has been working at St Vincent’s Hospital and at The University of New South Wales for 13 years. Late 2011, he co-initiated the creation of a new research Centre at Macquarie University: The Motor Neurone Disease (MND) Research Centre to undertake research in the fields of molecular and cellular neuroscience, with the goal of developing therapeutic strategies for MND and other neurodegenerative diseases. In 2012, he also co-created and managed the 1st MND biobank. He has been acting as Co-Director of the MND Centre for 5 years (2011-2016). In 2021, Prof Guillemin was one of the 5 lead scientists of the new Australian Research Council (ARC) Industrial Transformation Training Centre (ITTC) for Facilitated Advancement of Australia’s Bioactives (FAAB) aiming to work closely with various industries and biotech’s companies to test and assess natural products.

Our Core Facilities

We establish precise analytical test methods to ensure the integrity of your product. In the early-stage drug products we manufacture are often first-in-clinical, first-in-human products. This makes sterility assurance and safety data critical. We work to develop reliable test methods for factors like potency, percent encapsulation and degradation customized for your drug’s manufacturing and storage conditions.

1. Benchtop developmental work with new products at a small to medium scale

2. Analytics from sterility and stability testing, small batch size production for testing

3. In vitro (cellular) and in vivo (laboratory animal) testing platforms

4. Lyophilization of small to medium batches of products and medicines

5. TGA/APVMA consultative services

6. Intellectual Property investigative and enhancement consultancy

7. Australian Government Grant Application consultancy

8. NATA in house analytics

9. Proteomic testing

STRUCTURE

Australia has a rich history in research discoveries and early-stage translation. However, there is a growing need to develop the MedTech manufacturing capability nationally. RC@PG partners have significant expertise in implementation science and health economics to support evaluation of new evidence into practice.